Back to Energy
SupplementPreliminary evidenceEnergy

α-GPC (alpha-glycerophosphocholine)

Bioavailable choline source with preliminary RCT signal for cognitive function in mild dementia and acute power-output benefit.

Why

Alpha-glycerophosphocholine (α-GPC) is a bioavailable form of choline. The De Jesus Moreno 2003 RCT in Alzheimer-type mild dementia reported significant improvement on the ADAS-Cog at 180 days. A separate small body of work in healthy young adults supports acute power-output gains in athletic contexts (Bellar 2015). Larger and longer-duration trials in dementia have not yet been conducted.

How it works

Direct precursor to acetylcholine in cholinergic neurons, bypasses the rate-limiting choline-uptake step. Also provides glycerophosphate for membrane phospholipid synthesis. Crosses the blood-brain barrier efficiently relative to other choline sources.

Expected onset · Cognitive effects over 3–6 months in dementia trials; acute athletic effects within hours

How to take

Dosage

Cognition: 400 mg three times daily (De Jesus Moreno protocol). Power-output / athletic: 600 mg pre-exercise. Maintenance: 300–600 mg/day.

Timing

With meals; divided 2–3 times daily for cognitive use

On the label

Stated α-GPC content per dose (often labelled by total weight; 50% α-GPC is common). Distinct from CDP-choline (citicoline), different molecule.

Ideal for

Older adults with mild cognitive complaints exploring choline-pathway support; athletes interested in acute performance adjuncts.

Safety

Generally well tolerated. Possible mild headache, GI upset, restlessness. Possible interaction with cholinergic medications (donepezil, rivastigmine), additive effect. Pregnancy and breastfeeding data limited. Trimethylamine N-oxide (TMAO) elevation from choline excess is a theoretical cardiovascular concern at high chronic doses.

Evidence

At a glance

De Jesus Moreno 2003 RCT (n=261 mild-moderate Alzheimer dementia): α-GPC 400 mg three times daily for 180 days significantly improved ADAS-Cog and Mini Mental State scores vs placebo. Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation.

Limitations

Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation.

Where to get it

Shop α-GPC (alpha-glycerophosphocholine) on Amazon

Sponsored · As an Amazon Associate, Healicus earns from qualifying purchases.